Angiotensin II-Receptor Antagonists: An Overview

Raquel Dina and Mahtab Jafari

Disclosures

Am J Health Syst Pharm. 2000;57(13) 

In This Article

Instructions for the Patient

Women of childbearing age should be advised of the consequences of second- and third-trimester fetal exposure to AT-II-receptor antagonists and should be instructed to report their pregnancy to their physician as soon as possible. Patients taking losartan should be advised not to use potassium supplements or salt substitutes containing potassium because of the potential for increased serum potassium levels.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....